“Early stage GLP safety assessment can be a deal breaker” will be presented by Kendall Walker PhD. from Porsolt this week at the CNS Therapeutics Xchange in Boston. The roundtable discussion focuses on key aspects of early CNS drug development and the vital role of GLP safety when advancing CNS Therapeutics.
Kendall Walker PhD. and Stephen Morreale will also be meeting with scientists and key decision makers to discuss how Porsolt can enhance their drug development programs by including important GLP safety aspects in CNS therapeutics programs.
Please contact us to learn more about this important aspect of drug development or if you would like a summary of this important presentation: email@example.com
Or visit our website to learn more about our services and capabilities: www.porsolt.com